The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis.
 
William Fraser Symmans
Stock and Other Ownership Interests - Delphi Diagnostics; Eiger BioPharmaceuticals; ISIS Pharmaceuticals; Nuvera Biosciences
Consulting or Advisory Role - Almac Diagnostics; Merck
Patents, Royalties, Other Intellectual Property - Intellectual property; Intellectual Property (expired)
Travel, Accommodations, Expenses - Luminex; Merck
(OPTIONAL) Uncompensated Relationships - Delphi Diagnostics
 
Lili Du
No Relationships to Disclose
 
Tanya L. Hoskin
No Relationships to Disclose
 
Meenakshi Anurag
No Relationships to Disclose
 
Cynthia X. Ma
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Bayer; Biovica; Eisai; Novartis; Olaris; Philips Electronics; Puma Biotechnology; Sanofi; Seagen
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Isabelle Bedrosian
No Relationships to Disclose
 
Kelly Hunt
Consulting or Advisory Role - Armada Health Care; Merck
Research Funding - CairnSurgical (Inst); Endomagnetics (Inst); Lilly (Inst); Lumicell (Inst); OncoNano Inc (Inst)
 
Matthew James Ellis
Employment - Bioclassifier
Leadership - Bioclassifier
Stock and Other Ownership Interests - Bioclassifier
Consulting or Advisory Role - Foundation Medicine; G1 Therapeutics; Huron Consulting; Lilly; Novartis; Veracyte
Patents, Royalties, Other Intellectual Property - Patent on PAM50, which generates royalties on the license to Bioclassifier/Prosigna/Nanostring
 
Vera Jean Suman
Patents, Royalties, Other Intellectual Property - US Patent #10,220,016 B2 issued 3/5/2019 Methods and materials for assessing chemotherapy responsiveness and treatment cancer Applicant Mayo Foundation One of the inventors: Vera Suman (Inst)